Sunflower Pharmaceutical Group Co.Ltd(002737) 4 issued the annual report of 2021 in the evening of April 21. During the reporting period, the company achieved a revenue of 4.461 billion yuan, a year-on-year increase of 28.86%; The net profit attributable to the shareholders of the listed company was 705 million yuan, a year-on-year increase of 20.58%. The company plans to distribute a cash dividend of 7 yuan (including tax) for every 10 shares.
In 2021, Sunflower Pharmaceutical Group Co.Ltd(002737) continued to expand the business of children’s medication and continued to maintain its dominant position in the field of children’s medication. Focusing on the drug category cluster of “little sunflower” for children, gynecological drugs and drugs for chronic diseases in “sunflower” for adults, the company has arranged the product group, created a gold single product and built a large variety cluster.
Among them, the company acquired 6 varieties of children’s drugs in MAH mode; At the same time, through BD mode, it has obtained the Chinese agency rights of two drugs of Indian Ruidi pharmaceutical for children’s rare diseases, hexenoic acid oral solution powder and Quentin capsule, further broadening the field of “little sunflower” children’s medication. The company has also participated in and invested in Beijing famaxing Pharmaceutical Technology Co., Ltd., Zhuhai Zhongbao sunflower Pharmaceutical Technology Co., Ltd. and Chengdu Deyi Xinhua equity investment partnership (limited partnership).
During the reporting period, the company strengthened organizational reform, refined marketing channels and stimulated terminal vitality. Promote the implementation of strong regional marketing mode, promote the implementation of regional characteristics, and give more autonomy to the large area according to the characteristics of the company; A special line for children’s medication was set up in the brand mode, and a pediatric business department was established in the prescription mode. With the organization and mode as the guarantee, the company continued to strengthen its leading position in the field of children’s medication. At the same time, set up a professional team, actively layout new retail business, and explore the Internet and new retail oto mode.
The company set up a brand and digital marketing management center to upgrade, optimize and update the IP image of “little sunflower”. In terms of product management, continue to promote the marketing strategy of “gold single product cultivation + large variety cluster construction + category creation”; In terms of categories, focus on the “little sunflower” children’s drug category cluster, and the “sunflower” adult drug category cluster of gynecological drugs and chronic diseases, continue to improve the diagnosis and treatment promotion scheme, carry out category marketing and strengthen OTC end marketing.
During the reporting period, the company has carried out three consistency evaluations of chemical generic drugs. Among them, acetaminophen tablets passed the consistency evaluation; Amoxicillin granules has completed the human bioequivalence test (be), completed the CDE declaration and received the notice of supplementary information.
In order to do a good job in the key work in 2022, Sunflower Pharmaceutical Group Co.Ltd(002737) said that it would optimize the brand promotion strategy based on quality, realize the rejuvenation of the brand, and establish the core data index system of “little sunflower” brand; Continue to improve the recognition, reputation and trust of xiaosunflower brand, and strengthen brand leadership. Focus on the category of “little sunflower” drugs for children, the category of gynecological drugs and chronic diseases in “sunflower” adult drugs, implement the company’s established R & D strategy of “purchase, reform, joint research and generation”, take capital as the link, improve the category of children’s drugs and obtain heavy varieties through BD, MAH, strategic cooperation and other forms. At the same time, grasp the trend that the consumption attributes of OTC products are gradually enhanced, cultivate potential varieties, sprint advantageous varieties, create gold varieties, cast core varieties, improve product power and drive the continuous growth of category scale by further improving consumers’ medication experience.
The company will build a marketing structure and a marketing team according to the four marketing modes of prescription, brand, general medicine and great health. In terms of marketing strategy, continue to expand core categories and core varieties and seize the commanding height of retail. The OTC side focuses on the head chain, focuses on the increment, speeds up the cooperation, promotion and upgrading of the main products in the new retail section, and cooperates strategically with major new retailers to improve the overall position in the new retail category. The prescription side promotes academic transformation, promotes product upgrading, transmits product information, and focuses on the development of core hospital core products. The field of big health will continue to be guided by expanding varieties and categories, continuously optimize the product layout in terms of products, plan to introduce big health products suitable for the company’s strategy, and continue to make efforts in the big health market.
